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Abstract
Background: Lysophosphatidic acids (LPAs) are bioactive signaling phospholipids that have been implicated in
Alzheimer’s disease (AD). It is largely unknown whether LPAs are associated with AD pathology and progression
from mild cognitive impairment (MCI) to AD.
Methods: The current study was performed on cerebrospinal fluid (CSF) and plasma samples of 182 MCI patients
from two independent cohorts. We profiled LPA-derived metabolites using liquid chromatography-mass
spectrometry. We evaluated the association of LPAs with CSF biomarkers of AD, Aβ-42, p-tau, and total tau levels
overall and stratified by APOE genotype and with MCI to AD progression.
Results: Five LPAs (C16:0, C16:1, C22:4, C22:6, and isomer-LPA C22:5) showed significant positive association with
CSF biomarkers of AD, Aβ-42, p-tau, and total tau, while LPA C14:0 and C20:1 associated only with Aβ-42 and alkyl-
LPA C18:1, and LPA C20:1 associated with tau pathology biomarkers. Association of cyclic-LPA C16:0 and two LPAs
(C20:4, C22:4) with Aβ-42 levels was found only in APOE ε4 carriers. Furthermore, LPA C16:0 and C16:1 also showed
association with MCI to AD dementia progression, but results did not replicate in an independent cohort.
Conclusions: Our findings provide evidence that LPAs may contribute to early AD pathogenesis. Future studies are
needed to determine whether LPAs play a role in upstream of AD pathology or are downstream markers of
neurodegeneration.
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Background
Lipids play a key role in Alzheimer’s disease (AD) [1–3].
Lysophosphatidic acids (LPAs) are bioactive phospho-
lipids representing a significant class of signaling mole-
cules [4]. LPAs regulate a plethora of downstream
processes including brain immune response [5], myelin-
ation [6], synaptic transmission [7, 8], and synaptic plas-
ticity [9], as well as in endothelial cells and
neurovascular function [10]. A recent study has reported
altered levels of LPA C18:2 in AD patients compared to
controls in plasma [11] and LPAs have been implicated
in amyloid-beta (Aβ) formation [12] and phosphoryl-
ation of tau [13] as well, the neuropathological hallmarks
of AD. The LPAs may contribute to amyloid pathology,
which is supported by their role in enhancing Aβ pro-
duction through upregulation β-secretase expression
[12]. Moreover, as a bioactive component of oxidized
LDL (OxLDL), LPAs affect the integrity of the blood-
brain barrier [14] and are also involved in neuronal cell
death [15, 16]. The mounting evidence for the role of
LPA metabolites as a mediator in AD-related molecular
process underline their importance in AD pathophysi-
ology. Nevertheless, studies are lacking investigating the
relationship between LPA metabolites with AD bio-
markers of pathophysiology.
Encompassing a large group of related metabolites,
LPA (1 or 2-acyl-sn-glycero-3-phosphate) metabolites
comprises of an sn-glycerol-3 phosphate connected to a
fatty acid [17–19]. Molecular species of LPAs differ
based on their acyl chain length (C14 to C22) and de-
grees of saturation (C16:1, C18:1, C18:2, C20:3, C20:5,
C20:4, C22:4, C22:6) [20]. For example, C18:1 denoting
an acyl chain of 18 carbons with a double bond, while
C18:2 denotes an acyl chain of 18 carbons with two
double bonds [21, 22]. This structural diversity of LPAs
also imparts them with differential biological activity
[23–25]. Differential biological activity of LPAs can also
be attributed to their G-coupled-protein-receptors
(GCPR) ranging from LPA1–5, which differ in their affin-
ity and response to diverse LPA species [20, 25]. This
structure-activity relationship of LPAs may be relevant
to their role in AD pathophysiology [26]. A comprehen-
sive study of LPA metabolites in AD-related pathology is
lacking [14], and the interaction of apolipoprotein E
(APOE) has not been studied. It is also not known
whether LPAs play a role in the progression from mild
cognitive impairment (MCI) to AD dementia.
Our study aims to delineate the role of various LPA
species in AD during the prodromal phase of AD, i.e.,
MCI. We hypothesize that cerebrospinal fluid (CSF) and
plasma levels of LPAs may be associated to markers of
AD pathology, including to Aβ-42, phosphorylated tau
(p-tau), and total tau (t-tau) in MCI patients, and this as-
sociation may be modified by APOE gene. We further
hypothesized that LPAs might contribute to MCI to AD
dementia progression. As prior information on which
LPA species may be relevant for the hypothesis, we
assessed a series of structurally different LPA metabo-
lites in CSF and plasma.
Methods
Study populations
The current study was performed in cohorts participat-
ing in the Alzheimer’s Disease Apolipoprotein Pathology
for Treatment Elucidation and Development (ADAP
TED) consortium including the Barcelona-based mem-
ory clinic Fundació ACE (142 CSF-plasma paired sam-
ples) and the Department of Geriatric Psychiatry at the
Medical Faculty Mannheim, University of Heidelberg (40
CSF samples). Both participating studies are approved by
the medical ethical committee of their respective insti-
tutes and informed consents were collected from all par-
ticipants, which allow the use of phenotype and
biomarker information for research purpose. From both
participating cohorts, we selected MCI patients for
which complete information was available on age at
blood collection, sex, body mass index (BMI), and lipid-
lowering medication use, as well as AD biomarkers in
CSF (i.e., Aβ-42, p-tau, and total tau).
Fundació ACE cohort
All the MCI patients from the Fundació ACE (ACE) co-
hort were recruited and assessed between 2016 to 2017
at the Memory Disorders Unit from Fundació ACE,
Institut Català de Neurociènces Aplicades, Barcelona,
Spain [27]. Each patient was assigned a diagnosis after
consensus at a case conference attended by neurologists,
neuropsychologists, and social workers. MCI patients
fulfilled MCI Petersen’s diagnostic criteria [28, 29] in-
cluding subjective memory complaints, decline from
normal general cognition, preserved performance in ac-
tivities of daily living, absence of dementia, and a meas-
urable impairment in one or more cognitive functions,
with or without deficit in other cognitive domains
(amnestic MCI: single domain or amnestic MCI: mul-
tiple domain). At follow-up, dementia was defined ac-
cording to the DSM-V criteria [30]. The underlying
etiologies of the cognitive deficits within the dementia
group were classified according to the following criteria:
the 2011 National Institute of Aging-Alzheimer’s Associ-
ation (NIA-AA) [31] for Alzheimer’s disease and the Na-
tional Institute of Neurological Disorder and Stroke and
Association Internationale pour la Recherche et l’En-
seignement in Neurosciences criteria(NINDS-AIREN)
[32] for vascular dementia, frontotemporal dementia
[33], and Lewy body dementia [34].
Paired samples of CSF and plasma were collected from
patients under fasted conditions. CSF was obtained by
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lumbar puncture following the established consensus
recommendations [35]. Briefly, the lumbar puncture
(LP) was performed by an experienced neurologist with
the patients in a sitting position. After local anesthesia
(1% mepivacaine) was injected subcutaneously, CSF was
obtained by LP in the intervertebral space of L3-L4. The
fluid was collected passively in two 10-ml polypropylene
tubes (Sarstedt ref. 62610018). The first tube of CSF was
analyzed for basic biochemistry (glucose, total proteins,
proteinogram, and cell type and cell number). The sec-
ond tube was centrifuged (2000×g 10min at 4 °C), and
the fluid was aliquoted into polypropylene tubes (Sar-
stedt ref. 72694007) and stored at − 80 °C until analysis.
The time delay between CSF collection and storage was
less than 2 h. On the same day as the AD biomarker
analysis (Aβ-42, p-tau, and total tau), an aliquot was
thawed at room temperature and vortexed for 5–10 s.
CSF Aβ1–42, total tau, and p-tau levels were measured
using commercially available enzyme-linked immuno-
sorbent assays, namely Innotest Aβ1–42, Innotest hTAU
Ag, and Innotest PHOSPHO-TAU (181P) (Innotest,
Fujirebio Europe) [35, 36].
For APOE genotyping in the ACE cohort, genomic
DNA was obtained from whole blood collected in BD
Vacutainer tubes (K2-EDTA). DNA extraction was per-
formed using DNA Chemagen technology (Perkin
Elmer). Afterward, the APOE genotype was determined
by TaqMan probes analysis in a system of Real-Time
PCR QuantStudio3 (Thermofisher).
Heidelberg/Mannheim memory clinic sample
Forty MCI patients were recruited and assessed between
2012 to 2016 at the Memory Clinic of the Central Insti-
tute of Mental Health (Mannheim, Germany). Neuro-
psychiatric or general medical causes of impaired
cognition were excluded by detailed medical history,
physical and neuropsychiatric examination, and standard
serum laboratory assessment. Thus, all MCI patients
met the MCI Petersen’s diagnostic criteria [28, 29] in-
cluding subjective memory complaints, normal general
cognition, only minimally impaired performance in in-
strumental activities of daily living, absence of dementia,
and a measurable impairment in one or more cognitive
domains. Cognitive impairment was defined as perform-
ance below 1.2 standard deviation in one or more cogni-
tive domains in standard neuropsychological test battery
[37] (test battery of the Consortium to Establish a Regis-
try for Alzheimer Disease (CERAD) [38] plus the
Wechsler memory scale – logical memory (WMS) im-
mediate and delayed recall [39] and the trail making test
A (TMT-A) and B (TMT-B) [40]. For biomarker assess-
ments, lumbar puncture was performed to determine
amyloid pathology in CSF following the NIA/AA criteria
for the diagnosis of MCI due to AD [41]. The results of
the clinical assessment for each patient were discussed
at a case conference attended by geriatric psychiatrists
and neuropsychologists. The diagnosis of MCI due to
AD or prodromal AD [42] was assigned by consensus
using all clinical and biomarker data (CSF Aβ-42, t-tau,
and p-tau). Paired samples of CSF and plasma were col-
lected from patients according to the established consen-
sus recommendations [35]. Aliquots were stored in
polypropylene tubes at − 80 °C. Aβ1–42, p-tau, and t-tau
were performed in the Neurochemistry Laboratory at
the Department of Neurology, University Medical
School, Göttingen, using established protocols. P-tau
levels in CSF were quantified with a commercially avail-
able ELISA kit [INNOTEST® PHOSPHO-TAU(181P),
Innogenetics]. Aβ1–42 was detected with a commercially
available ELISA kit [INNOTEST®β- AMYLOID (1–42)
Innogenetics] for quantitative analysis.
APOE genotyping in Heidelberg/Mannheim memory
clinic sample was performed on an Illumina GSA1.0
SharedCustom Content bead array according to the
manufacturer’s instructions. GenomeStudio 2.0 software
was used to determine APOE genotypes and results were
exported in PLINK format.
Metabolomics profiling
All CSF and plasma samples of both cohorts were pro-
filed for the same set of metabolites using a UHPLC-
MS/MS approach targeting signaling lipid mediators in-
cluding LPAs, alkyl-lysophosphatidic acid (aLPAs), and
cyclic-lysophosphatidic acids (cLPAs) ranging from C14
to C22 acyl chain length [43].
Samples were stored at − 80 °C, thawed at room
temperature, and randomized prior to analysis. Quality
control (QC) samples, consisting of a pool of all samples,
and blanks were also analyzed to ensure the quality of
the obtained data. For CSF samples, 350 μL of samples
were evaporated to dryness, spiked with isotopically la-
beled internal standards and antioxidant (BHT:EDTA 1:
1, 0.2 mg/mL), and reconstituted in two aliquots using a
mixture of methanol to water (70:30, v/v). Plasma sam-
ples were first acidified through the addition of 0.2M
citric acid and 0.1M disodium hydrogen phosphate buf-
fer at pH 4.5. Metabolites were extracted using liquid-
liquid extraction with a mixture of 1-butanol:ethyl acet-
ate (1:1, v/v) prior to mixing, centrifugation, collection
of the supernatant, evaporation, and reconstitution into
two aliquots with a mixture of ice-cold methanol to
water (70:30, v/v).
Samples were measured using a Shimadzu LC-30 AD
system coupled to a LCMS-8050 Triple Quadrupole sys-
tem (Shimadzu, Japan).
For both plasma and CSF samples, the first aliquot
(high pH injection) was analyzed using a Kromasil
EternityXT-1.8 C18 column, 2.1 × 50mm, 1.8 μm (Akzo
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Nobel, Netherlands) with a mobile phase composed of (A)
water with 5mM ammonium acetate and 0.0625% ammo-
nium hydroxide and (B) 80% acetonitrile with 20% isopro-
panol and 0.1% ammonium hydroxide. For both matrices,
the second aliquot (low pH injection) was analyzed using
an Acquity BEH C18 column, 2.1 × 50mm, 1.7 μm (Wa-
ters) with a mobile phase composed of (A) water with 0.1%
acetic acid, (B) 75% acetonitrile with 25% methanol and
0.1% acetic acid, and (C) 100% isopropanol. For both pH
injections, polarity switching and dynamic multiple reaction
monitoring (dMRM) mode were used for MS acquisition.
To perform the QC, metabolites showing a relative
standard deviation (RSD) higher than 30% on corrected
peak areas in QC samples were excluded. After QC cor-
rection, 19 and 17 LPAs in CSF and plasma, respectively,
were used for further data analysis (Supplementary
Table 1). Common metabolites detected in both CSF
and plasma included LPAs (C14:0, C14:1, C14:2, C16:0,
C18:0, C18:1, C18:2, C20:1, C20:3, C20:5, C22:4, C22:5)
and three cyclic-LPAs (C16:0, C18:0, C18:1). Metabolites
only detected in CSF samples included some LPAs (C20:
4, C22:6, C22:5) and an alkyl-LPA C16:1. LPA C18:3 and
two cyclic-LPAs (C18:2, C20:4) were detected only in
plasma samples. The inverse rank transformation was
used to normalize the distribution of metabolites in both
cohorts.
Statistical analysis
Association of LPAs with Aβ-42, p-tau, and t-tau We
performed linear regression analysis to test the associ-
ation of Aβ-42, p-tau, and t-tau with the profiled metab-
olites in paired CSF and plasma samples from the ACE
cohort and CSF samples from Heidelberg-Manheim
memory clinic. Levels of Aβ-42, p-tau, and t-tau in CSF
were used as the outcome variable in the regression
model. Analyses were adjusted for age, sex, body mass
index (BMI), and lipid-lowering medications. The in-
verse rank transformation was applied to normalize the
distribution of both CSF AD biomarkers (Aβ-42, p-tau,
and t-tau) and LPA metabolite levels in CSF and plasma.
A meta-analysis of the regression analysis results of the
two cohorts was performed using METAL software [44]
using the inverse-variance fixed-effect model. Meta-
analysis results of associations were also corrected for
multiple testing separately for each AD biomarker using
false discovery rate (FDR) by the Benjamini and Hoch-
berg method [45] and findings with FDR < 0.05 were
considered significant in the overall analysis. All analyses
were performed in R (https://www.r-project.org/). To
test whether conversion from LPA to another was
relevant, we have tested all ratios between LPAs.
APOE-stratified regression analysis To identify
APOE-specific associations of metabolites with AD
biomarkers, APOE-stratified analyses were performed in
both participating cohorts based on three APOE strata
including APOE 44/34/24, APOE 33, and APOE 22/23.
In the stratified analyses, subjects with APOE 24 geno-
type were pooled with patients having APOE 44/34 ge-
notypes based on their similar risk profiles, as reported
in an earlier study [46]. APOE-stratified analyses results
were reported as a combined meta-analysis of both data-
sets included in the current study (ACE cohort and Hei-
delberg/Manheim cohort). Due to the smaller number of
APOE 22/23 carriers in the two datasets, a combined re-
gression analysis was performed, aggregating all APOE
22/23 carriers from two cohorts while adjusting for co-
hort effects. Multiple testing correction was performed
using the false-discovery rate (FDR < 0.05) based on Ben-
jamin and Hochberg [45].
To assess the association of the APOE genotype with
LPAs, we compared levels of LPAs in CSF of APOE ε4
(APOE 44/34/24) and APOE ε2 (22/23) carriers versus
APOE ε33 carriers using regression analysis adjusting for
the age, sex, BMI, and lipid-lowering medications. This
regression analysis was conducted for each cohort and
their combined meta-analysis.
MCI to AD dementia progression analysis In the ACE
cohort, follow-up information was available for 138 out
of 142 MCI patients including 17 non-amnestic and 121
amnestic MCIs. A total of 43 MCI patients progressed
into AD dementia (31%) during follow-up, while 95 MCI
patients did not convert to AD dementia. The mean
follow-up time in converters was 1.42 years (SD = 0.53)
and 1.44 years (SD = 0.70) in non-converters. The rate of
MCI to AD dementia progression in our sample is simi-
lar to other clinic-based studies [47]. We analyzed the
association of LPAs with MCI to AD dementia progres-
sion using the cox proportional hazard model adjusting
for age at blood collection, sex, BMI, and lipid-lowering
medication use. In the ACE cohort, 11 MCI patients also
progressed to other types of dementia including vascular
dementia (n = 6), semantic dementia (n = 1), Parkinson
dementia (n = 1), Lewy Body dementia (n = 2), and
frontal temporal dementia (n = 1). We repeated the con-
version analysis in the Heidelberg/Mannheim cohort.
Among the 40 MCIs, 23 converted to AD dementia. The
mean follow-up time in the Heidelberg/Mannheim co-
hort was 1.80 years (SD = 1.06). Three MCI patients also
progressed to frontal temporal dementia in this sample.
Association of cognitive measures with LPA levels
We also assessed the association of cognitive measures,
MMSE, and CDR with LPAs levels in CSF of both ACE
and Heidelberg/Mannheim cohort. We used linear re-
gression analysis adjusted for age, sex, BMI, and lipid-
lowering medication. Results were meta-analyzed using
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Table 1 Population descriptive
ACE cohort Heidelberg/Mannheim cohort P value of difference
MCI patients (N) 142 40
Metabolomics profiling tissue CSF and plasma CSF
Age (SD) blood collection, years 71.94 (7.74) 68.85 (8.50) 0.042
Female (%) 74 (52%) 22 (55%) 0.747
Body mass index (SD) 26.46 (3.74) 25.85 (3.61) 0.353
Lipid-lowering medication user (%) 63 (44%) 11 (27%) 0.055
Amyloid-beta 42 in pg/mL (SD) 791.59 (337.36) 690.84 (397.13) 0.151
P-Tau in pg/mL (SD) 71.37 (37.30) 63.17 (29.96) 0.153
Total tau in pg/mL (SD) 478.82 (253.45) 380.95 (326.97) 0.124
MMSE 24.93 (4.07) 26.55 (2.51) 2.67 × 10−3
CDR 0.50 (0.06) 0.55 (0.15) 0.047
APOE genotype N (%)
APOE 44/34/24 50 (35%) 18 (45%)
APOE 33 81 (57%) 18 (45%)
APOE 22/23 11 (8%) 4 (10%)
Abbreviations: MCI mild cognitive impairment, SD standard deviation, CSF cerebrospinal fluid, MMSE the Mini-Mental State Examination, CDR clinical dementia
rating, APOE apolipoprotein E gene
Table 2 Association of cerebrospinal fluid (CSF) level of metabolites with Aβ-42 levels in CSF
ACE cohort Heidelberg/Mannheim cohort Meta-analysis
β SE P value β SE P value β SE Direction P value FDR
LPA C18:1 0.286 0.100 4.85 × 10−3 0.260 0.199 2.00 × 10−1 0.281 0.089 ++ 1.65 × 10−3 1.26 × 10−2
LPA C16:1 0.264 0.087 2.81 × 10−3 0.150 0.175 3.97 × 10−1 0.242 0.078 ++ 1.88 × 10−3 1.26 × 10−2
LPA C16:0 0.249 0.081 2.61 × 10−3 0.134 0.209 5.27 × 10−1 0.234 0.076 ++ 2.00 × 10−3 1.26 × 10−2
LPA C22:6 0.199 0.086 2.19 × 10−2 0.372 0.181 4.76 × 10−2 0.231 0.078 ++ 2.91 × 10−3 1.38 × 10−2
LPA C14:0 0.220 0.092 1.76 × 10−2 0.232 0.175 1.92 × 10−1 0.223 0.081 ++ 6.04 × 10−3 2.29 × 10−2
LPA C22:4 0.150 0.084 7.59 × 10−2 0.393 0.184 4.02 × 10−2 0.191 0.076 ++ 1.20 × 10−2 3.79 × 10−2
LPA C20:4 0.211 0.096 2.91 × 10−2 0.178 0.165 2.89 × 10−1 0.203 0.083 ++ 1.44 × 10−2 3.90 × 10−2
Isomer-LPA C22:5 0.208 0.086 1.61 × 10−2 0.071 0.177 6.90 × 10−1 0.183 0.077 ++ 1.78 × 10−2 4.23 × 10−2
LPA C18:0 0.172 0.090 5.65 × 10−2 0.211 0.176 2.39 × 10−1 0.180 0.080 ++ 2.39 × 10−2 5.05 × 10−2
LPA C18:2 0.189 0.083 2.51 × 10−2 0.028 0.170 8.69 × 10−1 0.158 0.075 ++ 3.50 × 10−2 6.65 × 10−2
cLPA C18:1 0.170 0.093 7.03 × 10−2 0.055 0.186 7.68 × 10−1 0.147 0.083 ++ 7.77 × 10−2 1.34 × 10−1
LPA C22:5 0.112 0.088 2.04 × 10−1 0.230 0.179 2.09 × 10−1 0.135 0.079 ++ 8.70 × 10−2 1.35 × 10−1
LPA C20:1 0.164 0.092 7.59 × 10−2 0.038 0.175 8.29 × 10−1 0.137 0.081 ++ 9.21 × 10−2 1.35 × 10−1
cLPA C16:0 0.199 0.105 5.91 × 10−2 − 0.046 0.187 8.06 × 10−1 0.141 0.091 +− 1.23 × 10−1 1.67 × 10−1
aLPA C18:1 0.335 0.127 9.31 × 10−3 − 0.225 0.174 2.04 × 10−1 0.140 0.103 +− 1.72 × 10−1 2.17 × 10−1
cLPA C18:0 0.085 0.091 3.54 × 10−1 0.036 0.193 8.55 × 10−1 0.076 0.082 ++ 3.58 × 10−1 4.25 × 10−1
aLPA C16:1 0.199 0.132 1.35 × 10−1 − 0.106 0.166 5.30 × 10−1 0.081 0.103 +− 4.33 × 10−1 4.84 × 10−1
LPA C20:3 0.124 0.103 2.29 × 10−1 − 0.104 0.169 5.41 × 10−1 0.062 0.088 +− 4.77 × 10−1 5.04 × 10−1
LPA C20:5 − 0.114 0.090 2.08 × 10−1 0.253 0.185 1.80 × 10−1 − 0.044 0.081 −+ 5.88 × 10−1 5.88 × 10−1
Direction column indicates the direction of regression coefficient of association in the ACE and Heidelberg/Mannheim cohort respectively
Abbreviations: LPA lysophosphatidic acid, cLPA cyclic lysophosphatidic acid, aLPA alkyl-Lysophosphatidic acid, SE standard error, FDR false discovery rate
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METAL software [44] using the inverse-variance fixed-
effect model and multiple testing was performed using
false discovery rate (FDR) by the Benjamini and
Hochberg method [45].
Results
General characteristics
The general characteristic of the ACE and Heidelberg/
Mannheim cohorts are provided in Table 1. The patients
of the ACE cohort of Barcelona are on average 3 years
older (P = 0.042) than the Heidelberg/Mannheim cohort.
The proportion of women is similar between the two co-
horts (P = 0.747). The proportion of patients treated with
lipid-lowering medication in the ACE cohort (44%) is 1.6
times (P = 0.055) higher compared to that in the Heidel-
berg/Mannheim series of patients. The levels of Aβ-42, p-
tau, and t-tau in CSF between the two cohorts were not
significantly different. In terms of basic cognitive mea-
sures, the Mini-Mental State Examination (MMSE) score
(P = 2.67 × 10−3) and clinical dementia rating (CDR) score
(P = 0.047) was significantly higher in Heidelberg/Mann-
heim cohort compared to ACE cohort.
Association of LPAs with CSF Aβ-42, p-tau, and total tau
Findings of the association of the metabolites with Aβ-
42 levels in CSF are provided in Table 2. In a meta-
analysis, eight LPAs including C18:1 (β = 0.281, P =
1.65 × 10−3), C16:1 (β = 0.242, P = 1.88 × 10−3), C16:0
(β = 0.234, P = 2 × 10−3), C22:6 (β = 0.231, P = 2.91 ×
10−3), C14:0 (β = 0.223, P = 6.04 × 10−3), C22:4 (β = 0.191,
P = 1.20 × 10−2), C20:4 (β = 0.203, P = 1.44 × 10−2), and
isomer-LPA C22:5 (β = 0.183, P = 1.78 × 10−2) showed
positive association with Aβ-42 levels in CSF. The effect
estimates (β) of all associated LPAs were in the same
direction in both cohorts.
Six LPAs, C20:1 (β = 0.347, P = 7.11 × 10−6), isomer-
LPA C22:5 (β = 0.328, P = 8.68 × 10−6), C22:6 (β = 0.270,
P = 4.03 × 10−4), C16:0 (β = 0.230, P = 2.26 × 10−3), C16:1
(β = 0.206, P = 8.23 × 10−3), and C22:4 (β = 0.186, P =
1.39 × 10−2) showed significant association (FDR < 0.05)
with p-tau levels in CSF. In terms of the direction of ef-
fects, the regression coefficients (β) were very similar
across two cohorts (Table 3).
Findings for t-tau levels in CSF were very similar as
those for p-tau levels (Table 4), with five LPAs including
C20:1, isomer-LPA C22:5, C22:6, C16:0, C16:1, C22:4,
C18:1, and alkyl-LPA C18:1 showing significant positive
association (FDR < 0.05) with total tau levels in CSF.
Among the identified metabolites, LPA C18:1 and alkyl-
LPA C18:1 showed association with only total tau but
not with p-tau levels.
Table 3 Association of cerebrospinal fluid (CSF) level of metabolites with p-tau levels in CSF
ACE cohort Heidelberg/Mannheim cohort Meta-analysis
β SE P value β SE P value β SE Direction P value FDR
LPA C20:1 0.350 0.086 8.16 × 10−5 0.333 0.174 6.42 × 10−2 0.347 0.077 ++ 7.11 × 10−6 8.25 × 10−5
Isomer-LPA C22:5 0.302 0.082 3.15 × 10−4 0.438 0.170 1.46 × 10−2 0.328 0.074 ++ 8.68 × 10−6 8.25 × 10−5
LPA C22:6 0.279 0.083 9.39 × 10−4 0.214 0.198 2.88 × 10−1 0.270 0.076 ++ 4.03 × 10−4 2.55 × 10−3
LPA C16:0 0.218 0.080 7.67 × 10−3 0.316 0.214 1.48 × 10−1 0.230 0.075 ++ 2.26 × 10−3 1.07 × 10−2
LPA C16:1 0.226 0.086 9.49 × 10−3 0.112 0.182 5.43 × 10−1 0.206 0.078 ++ 8.23 × 10−3 3.13 × 10−2
LPA C22:4 0.168 0.082 4.17 × 10−2 0.287 0.196 1.53 × 10−1 0.186 0.076 ++ 1.39 × 10−2 4.40 × 10−2
LPA C18:1 0.217 0.099 3.08 × 10−2 0.171 0.212 4.25 × 10−1 0.209 0.090 ++ 2.04 × 10−2 5.54 × 10−2
aLPA C18:1 0.110 0.128 3.91 × 10−1 0.425 0.169 1.69 × 10−2 0.224 0.102 ++ 2.79 × 10−2 6.62 × 10−2
cLPA C18:0 0.159 0.089 7.53 × 10−2 0.243 0.197 2.26 × 10−1 0.173 0.081 ++ 3.23 × 10−2 6.82 × 10−2
LPA C20:3 0.072 0.101 4.79 × 10−1 0.380 0.163 2.62 × 10−2 0.157 0.086 ++ 6.77 × 10−2 1.29 × 10−1
cLPA C18:1 0.115 0.092 2.14 × 10−1 0.265 0.189 1.69 × 10−1 0.144 0.083 ++ 8.25 × 10−2 1.42 × 10−1
LPA C14:0 0.129 0.091 1.60 × 10−1 0.088 0.187 6.42 × 10−1 0.121 0.082 ++ 1.40 × 10–1 2.12 × 10−1
LPA C22:5 0.065 0.087 4.56 × 10−1 0.326 0.184 8.51 × 10−2 0.112 0.078 ++ 1.52 × 10−1 2.12 × 10−1
aLPA C16:1 0.061 0.131 6.42 × 10−1 0.287 0.168 9.65 × 10−2 0.146 0.103 ++ 1.56 × 10−1 2.12 × 10−1
LPA C18:0 0.096 0.089 2.82 × 10−1 0.077 0.188 6.86 × 10−1 0.092 0.080 ++ 2.50 × 10−1 3.16 × 10−1
LPA C18:2 − 0.094 0.083 2.60 × 10−1 −0.024 0.175 8.90 × 10−1 − 0.081 0.075 – 2.79 × 10−1 3.30 × 10−1
cLPA C16:0 0.102 0.104 3.28 × 10−1 0.075 0.196 7.04 × 10−1 0.096 0.092 ++ 2.95 × 10−1 3.30 × 10−1
LPA C20:4 0.077 0.095 4.20 × 10−1 0.081 0.176 6.49 × 10−1 0.078 0.084 ++ 3.53 × 10−1 3.72 × 10−1
LPA C20:5 − 0.028 0.088 7.54 × 10−1 0.114 0.193 5.59 × 10−1 − 0.003 0.081 −+ 9.68 × 10−1 9.68 × 10−1
Direction column indicates the direction of regression coefficient of association in the ACE and Heidelberg/Mannheim cohort respectively
Abbreviations: LPA lysophosphatidic acid, cLPA cyclic lysophosphatidic acid, aLPA alkyl-Lysophosphatidic acid, SE standard error, FDR false discovery rate
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Figure 1a shows a heatmap comparing Aβ-42, p-tau,
and t-tau in CSF. The pattern of association is very simi-
lar for amyloid and tau biomarkers except for two LPAs
(C14:0, C20:4) showing association to only Aβ-42 and an
alkyl-LPA C18:1 showing a unique relation to total tau
levels in CSF. Correlation plots are provided in Fig. 1 for
five LPAs (C16:0. C16:1, C22:4, C22:6, isomer-LPA C22:
5), which showed significant association with all three
AD biomarkers (Aβ-42, p-tau, and t-tau). The analysis of
the ratios did not yield any significant findings.
In the regression analysis of LPAs in plasma (Supplemen-
tary Table 2), no significant association was found with Aβ-
42, p-tau, or with t-tau in ACE cohort. Correlation analysis
between CSF and plasma levels of LPAs for which paired
samples were available (Supplementary Fig. 1) shows that
levels of 8 LPAs were significantly correlated between CSF
and plasma: cyclic-LPA C16:0 (R = − 0.28, P = 9.4 × 10−4),
cyclic-LPA C18:1 (R = − 0.18, P = 0.029), LPA C18:1 (R =
0.44, P = 4.5 × 10−8), LPA C20:1 (R = − 0.23, P = 6.2 × 10−3),
and LPA C20:5 (R = 0.4, P = 1.2 × 10−6).
The role of APOE in the association between LPA levels
and CSF AD biomarkers
The results of meta-analysis of association results of
APOE-stratified analyses are provided in Fig. 2. APOE-
stratified analysis of Aβ-42 (Fig. 2a) showed that LPAs
species which showed significant association in the over-
all meta-analysis (C14:0, C16:0, C16:1, C18:1, C20:4,
C22:4, C22:6, isomer-LPA C22:5) were restricted to
APOE ε33 (LPA C16:0, C18:0, C22:6, isomer-LPA C22:5)
and APOE ε4 (LPA C20:4, C22:4) carriers while in APOE
22/23 carriers, the association was not significant and in
the opposite direction. Based on statistical significance,
we observed a few unique associations in the APOE4
stratum involving a cyclic-LPA C16:0 and in the
APOE33 stratum LPAs C18:0, which did not show sig-
nificant association in overall regression analysis. Al-
though the level of statistical significance differed
between APOE ε33 and APOE ε4 carriers, the direction
of association was always similar.
For p-tau and t-tau levels, significant association was
observed with isomer-LPA C22:5 in APOE 33 and APOE
ε4 carriers (Fig. 2b, c). Further significant association
was observed between LPA C20:1 and p-tau and three
LPAs (C16:0, C16:1, C22:4) and t-tau only in APOE 33
carriers.
As APOE appeared to modify the association between
various metabolites and CSF biomarkers, we tested
whether the APOE genotype is associated with levels of
the metabolites associated with biomarkers in the overall
and APOE-stratified analyses (see Supplementary Table 3
and 4). We did not observe significant differences
Table 4 Association of cerebrospinal fluid (CSF) level of metabolites with t-tau levels in CSF
ACE cohort Heidelberg/Mannheim cohort Meta-analysis
β SE P value β SE P value β SE Direction P value FDR
LPA C20:1 0.318 0.085 2.89 × 10−4 0.391 0.181 3.76 × 10−2 0.331 0.077 ++ 1.79 × 10−5 3.40 × 10−4
Isomer-LPA C22:5 0.271 0.081 1.05 × 10−3 0.390 0.184 4.14 × 10−2 0.290 0.074 ++ 8.88 × 10−5 8.07 × 10−4
LPA C22:6 0.268 0.081 1.22 × 10−3 0.409 0.200 4.84 × 10−2 0.288 0.075 ++ 1.27 × 10−4 8.07 × 10−4
LPA C16:0 0.227 0.079 4.42 × 10−3 0.461 0.218 4.18 × 10−2 0.254 0.074 ++ 5.80 × 10−4 2.75 × 10−3
LPA C16:1 0.236 0.084 5.67 × 10−3 0.280 0.187 1.44 × 10−1 0.244 0.077 ++ 1.48 × 10−3 5.63 × 10−3
LPA C22:4 0.185 0.080 2.21 × 10−2 0.361 0.203 8.51 × 10−2 0.209 0.074 ++ 5.05 × 10−3 1.60 × 10−2
LPA C18:1 0.230 0.097 1.93 × 10−2 0.190 0.223 3.99 × 10−1 0.224 0.089 ++ 1.20 × 10−2 3.26 × 10−2
aLPA C18:1 0.125 0.125 3.18 × 10−1 0.488 0.175 8.52 × 10−3 0.248 0.102 ++ 1.46 × 10−2 3.48 × 10−2
LPA C20:3 0.070 0.099 4.83 × 10−1 0.504 0.163 4.06 × 10−3 0.187 0.085 ++ 2.78 × 10−2 5.86 × 10−2
LPA C14:0 0.156 0.089 8.13 × 10−2 0.196 0.194 3.19 × 10−1 0.163 0.081 ++ 4.36 × 10−2 7.58 × 10−2
cLPA C18:0 0.166 0.087 5.88 × 10−2 0.140 0.210 5.11 × 10−1 0.162 0.080 ++ 4.39 × 10−2 7.58 × 10−2
aLPA C16:1 0.093 0.128 4.70 × 10−1 0.377 0.172 3.54 × 10−2 0.194 0.103 ++ 5.89 × 10−2 9.32 × 10−2
cLPA C18:1 0.110 0.090 2.26 × 10−1 0.202 0.201 3.21 × 10−1 0.126 0.082 ++ 1.28 × 10−1 1.87 × 10−1
LPA C20:4 0.084 0.094 3.68 × 10−1 0.245 0.180 1.83 × 10−1 0.119 0.083 ++ 1.54 × 10−1 2.08 × 10−1
LPA C18:0 0.112 0.087 2.01 × 10−1 0.050 0.198 8.03 × 10−1 0.102 0.080 ++ 2.01 × 10−1 2.55 × 10−1
LPA C22:5 0.026 0.085 7.59 × 10−1 0.407 0.189 3.88 × 10−2 0.090 0.078 ++ 2.46 × 10−1 2.92 × 10−1
cLPA C16:0 0.110 0.102 2.83 × 10−1 0.021 0.207 9.18 × 10−1 0.092 0.091 ++ 3.11 × 10−1 3.48 × 10−1
LPA C18:2 − 0.041 0.082 6.19 × 10−1 0.106 0.183 5.66 × 10−1 − 0.016 0.075 −+ 8.27 × 10−1 8.60 × 10−1
LPA C20:5 − 0.007 0.087 9.39 × 10−1 0.128 0.203 5.34 × 10−1 0.014 0.080 −+ 8.60 × 10−1 8.60 × 10−1
Direction column indicates the direction of regression coefficient of association in the ACE and Heidelberg/Mannheim cohort respectively
Abbreviations: LPA lysophosphatidic acid, cLPA cyclic lysophosphatidic acid, aLPA alkyl-Lysophosphatidic acid, SE standard error, FDR false discovery rate
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between APOE ε4 versus APOE ε33 carriers and APOE
ε2 versus APOE 33 carriers in the combined meta-
analysis of the two datasets. Although cLPA C18:1
showed suggestive association with APOE ε2 in the com-
bined meta-analysis (β = − 0.636, P = 4.66 × 10−3, FDR =
8.85 × 10−2) but did not pass multiple testing.
MCI to AD dementia progression
In the ACE cohort, LPA C16:1 (β = − 0.472, P = 3.25 ×
10−3, FDR = 4.41 × 10−2) and LPA C16:0 (β = − 0.412,
P = 4.64 × 10−3, FDR = 4.41 × 10−2) were significantly
associated with progression from MCI to AD demen-
tia (Supplementary Table 5). LPA C16:1 and C16:0
levels in CSF are correlated with each other (Supple-
mentary Fig. 2), which is also evident from their simi-
lar regression coefficient in the progression analysis.
As a sensitivity analysis, we also performed cox pro-
portional hazard analysis, additionally correcting for
APOE (Supplementary Table 6) and Aβ-42 levels in
CSF (Supplementary Table 7) to assess the role of
LPAs in MCI to AD progression. APOE did not affect
the association of LPA C16:0 and C16:1 to MCI to
AD dementia progression while the association was
lost upon adjusting for Aβ-42 levels. In plasma, LPA
C20:1 (β = 0.599, P = 1.84 × 10−2) showed evidence of
association to MCI to AD dementia progression but
significance was lost upon adjusting for multiple test-
ing (Supplementary Table 8). In the Heidelberg/
Mannheim sample (Supplementary Table 9), we did
not replicate our findings from ACE cohort, i.e., LPA
C16:1 (β = 0.457, P = 8.91 × 10−2) and LPA C16:0 (β =
0.431, P = 1.96 × 10−1).
Association of cognitive measures with LPA levels
We did not find significant association of LPA levels in
CSF with MMSE and CDR score in the combined meta-
Fig. 1 a Heatmap of overall meta-analysis of regression analysis results of metabolites with Aβ-42, p-tau, and t-tau levels in cerebrospinal fluid
(CSF). Star indicates significant association with false discovery rate < 0.05. b Scatter plots of correlation between LPAs (C16:0. C16:1, C22:4, C22:6,
isomer-LPA C22) with Aβ-42, p-tau, and t-tau levels in CSF
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analysis (Supplementary Tables 10 and 11). In individual
cohorts, only alkyl-LPA C16:1 showed evidence of asso-
ciation with MMSE (β = 0.253, P = 4 × 10−2) in ACE co-
hort and with CDR score (β = 0.254, P = 6.01 × 10−3) in
Heidelberg/Mannheim sample.
Discussion
Meta-analysis of the data of two independent cohorts
showed a significant association of eight LPAs to Aβ-42,
six LPAs to p-tau, and eight LPAs to t-tau levels in CSF.
In the APOE-stratified meta-analysis, one cyclic LPA
C16:0 and two LPAs (C20:4, C22:4) associate signifi-
cantly with Aβ-42 levels in APOE ε4 carriers only. The
association of LPAs with p-tau and total tau were
confined to APOE ε33 carriers except for isomer-LPA
C22:5, which showed association in both APOE33 and
APOE4 strata. LPA C16:0 and C16:1 were associated
with the progression of MCI to AD in the ACE cohort
but the association was no longer significant after adjust-
ing for Aβ-42 in the model.
The positive association between various LPAs and
Aβ-42 is in line with the findings of an earlier study,
suggesting that LPAs play a role in Aβ production by
upregulation of β-secretase (BACE1) [12], a key enzyme
involved in the cleavage of amyloid precursor protein
(APP). Our study pinpoints a key role of LPA C18:1,
C16:1, C16:0, C22:6, C14:0, C22:4, C20:4, and isomer-
LPA C22:5 in CSF amyloid levels, detailing which
Fig. 2 Heatmap of APOE-stratified meta-analysis of regression analysis results of metabolites with Aβ-42 (a), p-tau (b), and t-tau (c) levels in
cerebrospinal fluid. Star indicates significant association with false discovery rate < 0.05 in each stratum
Ahmad et al. Alzheimer's Research & Therapy          (2020) 12:124 Page 9 of 13
specific LPAs are relevant. The association of LPA to
CSF amyloid sheds new light on the role of (signaling)
lipids in AD pathogenies. LPAs are a bioactive compo-
nent of oxLDL, which show a positive correlation with
CSF levels of Aβ [48]. Moreover, traumatic brain injury
(TBI) patients also exhibit increased CSF levels of LPAs
[49]. Because amyloid pathology is observed in nearly
30% of TBI patients with unknown mechanisms [50],
our observed positive association of amyloid pathology
and LPA may suggest the role of LPAs as a mediator in
the aggregation of amyloid pathology, which needs fur-
ther investigation. On the other hand, Aβ may increase
oxidative stress and inflammation, which results in the
production of LPAs. There is a need for functional stud-
ies to ascertain whether the positive correlation between
amyloid and LPA is a cause or consequence of patho-
logical process.
In our study, CSF levels of LPAs (C16:0 and C16:1)
were significantly associated with MCI to AD dementia
progression in the ACE cohort. Similar to the inverse re-
lation of CSF Aβ-42 levels in MCI to AD dementia pro-
gression, decreased levels of the LPAs are associated
with MCI to AD dementia progression [51]. Loss of as-
sociation of LPAs with MCI to AD dementia progression
when accounting for Aβ-42 levels suggests that Aβ-42
mediates the observed association of LPA C16:0 and
C16:1 in conversion. This is of note that LPA 16:0 and
16:1 did not show significant association with MCI to
AD progression in the smaller Heidelberg/Mannheim
sample. However, LPA 16:0 and 16:1 also did not show
significant association with Aβ-42 levels in this small co-
hort, making findings difficult to interpret. The fact that
the association LPA C16:0 and C16:1 to conversion loses
its significance when adjusting for Aβ-42 levels suggests
the LPA C16:0 and C16:1 are likely preceding the
changes in Aβ-42 that predict conversion to AD.
In the APOE-stratified analysis, LPA C16:1 showed a
positive association to Aβ-42 levels in both APOE ε4 and
APOE ε33 carriers, whereas LPA C16:0 showed signifi-
cant positive association in only APOE ε3 stratum. No
effect of the ratio of these two correlated LPAs was seen.
The findings imply that the association of these LPAs to
Aβ-42 levels may be modified by APOE genotype of the
person. To our knowledge, this is the first study that
shows the APOE interacts with LPA in humans. Interest-
ingly, all LPA showed a negative association with Aβ-42
in APOE ε2 carriers, i.e., in the opposite direction com-
pared to APOE ε33 and APOE ε4 carrier. Since APOE ε2
carriers are protected from AD and have delayed onset
of AD [46], LPA modification may be relevant in APOE
ε33 and APOE ε4 carriers. We did not observe an associ-
ation of the interacting LPAs with APOE genotypes,
which may be due to a limited sample size in these
analyses.
Except for LPA C16:0, we found that the majority of
unsaturated LPAs (C16:1, C20:1, isomer-LPA C22:5,
C22:6, and C22:4) showed significant association to both
p-tau and total tau levels in CSF. Due to differential acti-
vation of LPA receptors by diverse LPA metabolite spe-
cies [23], association of unsaturated LPAs with AD
biomarkers of pathophysiology can also be explained by
their affinity for LPA3 receptors [52] which are also
expressed in hippocampus, frontal cortex, and amygdala
[53]. Moreover, both saturated and unsaturated LPAs
are reported to influence Ca2+ signaling through LPA2
receptors [52], which may also suggest their involvement
in the dysregulation of Ca2+ signaling in AD. Earlier
studies have shown that LPAs acts as mediators to main-
tain the intracellular Ca2+ levels in both astrocytes [54]
and microglial cells [5, 55]. One of these LPAs (LPA
C20:1) only showed significant association with p-tau
and total tau levels but not with Aβ-42. These tau spe-
cific associations may be explained by the fact that LPAs
are involved in the upregulation of glycogen synthase
kinase-3 (GSK-3), an enzyme involved in phosphoryl-
ation of tau and thus may influence levels of p-tau in
CSF [13, 56]. The association of LPA C20:1 to only tau
pathology may also indicate the specificity of association
of LPA species of different acyl chains to different AD
pathophysiological mechanisms. In the APOE-stratified
meta-analysis, all the observed associations were largely
confined to APOE ε33 carriers except for isomer-LPA
C22:5. This observation is in line with the studies which
demonstrated that APOE ε4 may influence amyloid path-
ology in the brain rather than tau aggregation [57–59].
We did not observe association of LPA levels in
plasma with Aβ-42, p-tau, and total-tau in CSF nor did
we find association with MCI to AD dementia progres-
sion. It is interesting that we observed a significant cor-
relation between CSF and plasma measurements of
various LPA molecular species. A negative correlation
was observed for cyclic-LPA C16:0, cyclic-LPA C18:1,
and LPA C20:1. Of these, the association was strongest
and most convincing for LPA C20:1 in terms of R
(− 0.23) and p value 6.2 × 10−3. The positive correlations
are more convincing in particular for LPA C18:1 (R = 0.44
and P = 4.5 × 10−8) and C20:5(R = 0.40 and P = 1.2 × 10−6)
and LPA 22:4 (R = 0.27 and P = 1.2 × 10−3) (Supplemen-
tary Fig. 1). LPAs found associated with Aβ, p-tau and t-
tau in CSF were not correlated with their counterparts in
plasma, which indicates that the LPA role in relation to
AD pathology is primarily cerebral and not in the
circulation.
Our study provides a comprehensive overview of asso-
ciation of various LPA species including alkyl-LPAs and
cyclic-LPAs to biomarkers of AD during the prodromal
phase. The inclusion of two independent cohorts is a
major strength of our investigation, allowing us to check
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consistency of effect across cohorts. Moreover, we have
also assessed the role of LPAs longitudinally for MCI to
AD dementia progression in the ACE cohort.
Limitations
The short follow-up time for MCI patients in the pro-
gression study is a limitation of our study and asks for
replication in a study with longer follow-up. The small
sample size in MCI to AD progression analysis is an-
other major limitation of our study. In the absence of
any data on the association between LPA and AD bio-
markers in CSF, we did not perform a power calculation
a priori, which limits the clinical and predictive implica-
tions of the discovery analysis. Future large sample sizes
in follow-up studies will also provide more power to per-
form APOE-stratified analysis.
Conclusions
Overall findings from our study suggest that various
LPAs based on acyl chain length and saturation level are
associated with Aβ-42, p-tau, and total tau levels. Our
study suggests the role of LPAs in the pathophysiology
of AD. Future studies are needed to determine whether
LPA metabolites triggers various biological pathways
leading to increase in biomarkers of AD pathophysiology
or are produced as a downstream effect of AD path-
ology. We further find that APOE may influence the as-
sociation between LPAs and Aβ-42.
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